Krystal Biotech vs Roivant Sciences
Krystal Biotech reported revenue of $389 million in fiscal 2025, 46.9 times Roivant Sciences' $8 million in fiscal 2025. Krystal Biotech's revenue grew 33.9% in its latest year, and Roivant Sciences' fell 71.6%. Krystal Biotech had an operating margin of 41.5%, against -6235.7% at Roivant Sciences. Free cash flow was $189 million at Krystal Biotech and −$759 million at Roivant Sciences. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Krystal Biotech | Roivant Sciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Mar 31, 2026 |
| Revenue | $389M | $8M |
| Revenue growth | 33.9% | −71.6% |
| Revenue growth a year, last 5 years | — | −19.0% |
| Gross margin | — | — |
| Operating margin | 41.5% | −6,235.7% |
| Net margin | 52.6% | −3,629.2% |
| Free cash flow | $189M | −$759M |
| Free cash flow margin | 48.5% | −9,183.5% |
| Return on capital | 43.6% | −62.6% |
| Net debt to EBITDA | −5.0x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.7% | −4.3% |
| Last close | $313.66 | $36.05 |
| P/E at the last close | 39.3× | — |
| Insider trades, last 12 months | sold $105.3 million | sold $582.4 million |
| Piotroski F-score | 5 of 8 | 1 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Krystal BiotechRoivant Sciences
Operating margin
Percent of revenue
Krystal BiotechRoivant Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Krystal BiotechRoivant Sciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Krystal Biotech and Roivant Sciences pages.